Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R).
http://bit.ly/1vqtQjJ
No comments:
Post a Comment